In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Xueting YaoDongyang Liu

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2-infected Vero cells. Physiologically based pharmacokinetic (PBPK) models were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile. Hydroxychloroquine (EC50 = 0.72 μM) was found to be more potent than chloroquine (EC50 = 5.47 μM) in vitro. Based on PBPK models result...Continue Reading

Associated Clinical Trials

Jul 30, 2020·sultan mehmood kamransultan mehmood kamran

References

Sep 1, 1979·The Journal of Cell Biology·J QuintartP Baudhuin
Mar 1, 1992·Human & Experimental Toxicology·P J NeuvonenK Pyykkö
Jun 1, 1989·British Journal of Clinical Pharmacology·S E TettK F Brown
Jul 18, 1983·The American Journal of Medicine·E W McChesney
Apr 1, 1983·British Journal of Clinical Pharmacology·L L GustafssonF Sjöqvist
Jan 1, 1982·General Pharmacology·S A Adelusi, L A Salako
Oct 1, 1993·Seminars in Arthritis and Rheumatism·R I Fox
Nov 1, 2003·The Lancet Infectious Diseases·Andrea SavarinoRoberto Cauda
Aug 24, 2004·Current Pharmaceutical Design·Frank RomanelliArdis Dee Hoven
Sep 8, 2004·Biochemical and Biophysical Research Communications·Els KeyaertsMarc Van Ranst
Aug 24, 2005·Virology Journal·Martin J VincentStuart T Nichol
Apr 28, 2006·Journal of Medicinal Chemistry·Christophe BiotErik De Clercq
May 30, 2006·Virology Journal·Eng Eong OoiRobert C S Chua
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Apr 23, 2014·Chemico-biological Interactions·Amal Kamal Abdel-AzizAshraf B Abdel-Naim
Feb 14, 2018·The Journal of Pharmacology and Experimental Therapeutics·Keagan P CollinsDaniel L Gustafson
Jan 25, 2020·The New England Journal of Medicine·Na ZhuUNKNOWN China Novel Coronavirus Investigating and Research Team
Feb 9, 2020·Nature Reviews. Rheumatology·Eva Schrezenmeier, Thomas Dörner
Mar 4, 2020·Lancet·Lianhan ShangBin Cao

❮ Previous
Next ❯

Citations

Mar 24, 2020·Nature Nanotechnology·Tony Y HuJoy Wolfram
Apr 3, 2020·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Bruno Mégarbane
Apr 8, 2020·Circulation Research·Akbarshakh Akhmerov, Eduardo Marban
Mar 27, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pasquale PaglianoAmelia Filippelli
Mar 27, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Maurizio Guastalegname, Alfredo Vallone
Mar 28, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xia Chen
Apr 17, 2020·Clinical Pediatrics·Priyank J YagnikPooja H Desai
Apr 9, 2020·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nicholas Moore
Apr 19, 2020·British Journal of Clinical Pharmacology·Patrick F SmithCraig Rayner
Apr 21, 2020·British Journal of Clinical Pharmacology·Géssica Vasconcelos GodinhoLuiz Evaristo Ricci Volpato
Apr 16, 2020·Pharmaceuticals·Jean Jacques Vanden Eynde
Apr 28, 2020·Journal of Thrombosis and Thrombolysis·Richard C Becker
Apr 14, 2020·International Journal of Rheumatic Diseases·Sanket ShahVir Singh Negi
Apr 28, 2020·Emerging Microbes & Infections·Xiaoxuan SunMiaojia Zhang
Apr 29, 2020·Journal of Primary Care & Community Health·Zach Sartor, Burritt Hess
Apr 30, 2020·International Reviews of Immunology·Alex ShneiderAnna Vakhrusheva
May 1, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Eric A MeyerowitzMark C Poznansky
Apr 23, 2020·Journal of the Pediatric Infectious Diseases Society·Kathleen ChiotosMari M Nakamura
Apr 4, 2020·Annals of the Rheumatic Diseases·Francesca Romana SpinelliFabrizio Conti
May 8, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Giovanni DianaFilippo Crea
Apr 29, 2020·Lupus Science & Medicine·Anca D AskanaseJill P Buyon
Apr 9, 2020·Clinical and Translational Science·Samuel L M Arnold, Frederick Buckner
May 12, 2020·JAMA : the Journal of the American Medical Association·Eli S RosenbergHoward A Zucker
Apr 30, 2020·Journal of Internal Medicine·Giuseppe PascarellaFelice Eugenio Agrò
May 14, 2020·The New England Journal of Medicine·Meghan E SiseEugene P Rhee
May 15, 2020·Journal of Orthopaedic Surgery·Colin Shing-Yat YungYat Wa Wong
Apr 9, 2020·Pharmacotherapy·Thomas P Lodise, Michael J Rybak
Apr 8, 2020·Pharmacotherapy·Ashley BarlowMojdeh S Heavner
May 18, 2020·The Journal of Antimicrobial Chemotherapy·M LahouatiF Bonnet
May 20, 2020·Eye·Susan M DownesHélène Dollfus
Apr 23, 2020·Annals of the Rheumatic Diseases·Sergey MoiseevVictor Fomin
Apr 30, 2020·Clinical Pharmacology and Therapeutics·Joseph F Standing
May 7, 2020·Rheumatology·Bruno LucchinoFabrizio Conti
Apr 23, 2020·Annals of the Rheumatic Diseases·Wenhui XieZhuoli Zhang
May 26, 2020·Journal of Biomolecular Structure & Dynamics·Satyajit Beura, Prabhakar Chetti
Jun 2, 2020·Expert Review of Clinical Immunology·Megan R W Barber, Ann E Clarke
Apr 30, 2020·Nature Reviews. Immunology·Matthew Zirui TayLisa F P Ng
May 19, 2020·Expert Review of Anti-infective Therapy·Shio-Shin Jean, Po-Ren Hsueh
Jun 4, 2020·The New England Journal of Medicine·David R BoulwareKathy H Hullsiek
Jun 5, 2020·Reviews in Medical Virology·Muhammad Muzamil KhanMudassir Shafiq
May 22, 2020·Acta Paediatrica·Carlos E Rodríguez-MartínezRafael Leite Pacheco
Jun 6, 2020·Journal of Investigative Medicine High Impact Case Reports·Asim KichlooShantanu Solanki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Xia Chen
Archives of Ophthalmology
Nicholas M HickleyMartin McKibbin
Acta Universitatis Palackianae Olomucensis Facultatis Medicae
M GrundmannP Vrublovský
International Journal of Antimicrobial Agents
Philippe ColsonDidier Raoult
© 2021 Meta ULC. All rights reserved